Key facts
- This page summarizes Samsara BioCapital GP, LLC's Form 4 filing for Neurogene Inc. (NGNE).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 27 Nov 2024, 16:39.
Samsara BioCapital GP, LLC - 26 Nov 2024 Form 4 Insider Report for Neurogene Inc. (NGNE)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- NGNE
- Reported as of
- 26 Nov 2024
- Net transaction value
- +$1,259,623
- SEC form
- 4
- Accepted by SEC
- 27 Nov 2024, 16:39:29 UTC
- Prior SEC filing
- 27 Nov 2024
- Next SEC filing
- 17 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- Samsara BioCapital GP, LLC, By /s/ Srinivas Akkaraju, Managing Member
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Samsara BioCapital GP, LLC filed Form 4 for Neurogene Inc. (NGNE) on 27 Nov 2024.
Change
- Previous filing in this sequence was filed on 27 Nov 2024.
- Current net transaction value: +$1,259,623.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NGNE
transaction
Common Stock
Purchase
- Transaction value
- $516,833
- Shares
- +20,748
- Change %
- +1.2%
- Price
- $24.91
- Shares after
- 1,689,105
- Date
- 26 Nov 2024
- Ownership
- By Samsara BioCapital, L.P.
- Footnotes
- F1, F2
NGNE
transaction
Common Stock
Purchase
- Transaction value
- $280,986
- Shares
- +10,803
- Change %
- +0.64%
- Price
- $26.01
- Shares after
- 1,699,908
- Date
- 26 Nov 2024
- Ownership
- By Samsara BioCapital, L.P.
- Footnotes
- F2, F3
NGNE
transaction
Common Stock
Purchase
- Transaction value
- $406,804
- Shares
- +15,219
- Change %
- +0.9%
- Price
- $26.73
- Shares after
- 1,715,127
- Date
- 26 Nov 2024
- Ownership
- By Samsara BioCapital, L.P.
- Footnotes
- F2, F4
NGNE
transaction
Common Stock
Purchase
- Transaction value
- $55,000
- Shares
- +2,000
- Change %
- +0.12%
- Price
- $27.50
- Shares after
- 1,717,127
- Date
- 26 Nov 2024
- Ownership
- By Samsara BioCapital, L.P.
- Footnotes
- F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.25 to $25.23 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Footnote F2
Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
Footnote F3
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.47 to $26.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Footnote F4
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Footnote F5
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.